Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase). (Q30868173)

27 June 2017

title

Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase). (English)

1 reference

27 June 2017

1 reference

8

Anders Hallberg

1 reference

27 June 2017

Anja Johansson

1

1 reference

27 June 2017

Anton Poliakov

2

1 reference

27 June 2017

Eva Akerblom

3

1 reference

27 June 2017

Gunnar Lindeberg

4

1 reference

27 June 2017

Susanne Winiwarter

5

1 reference

27 June 2017

Bertil Samuelsson

6

1 reference

27 June 2017

U Helena Danielson

7

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Bioorganic & Medicinal Chemistry

27 June 2017

published in

1 reference

27 June 2017

volume

10

1 reference

27 June 2017

issue

12

1 reference

27 June 2017

page(s)

3915-3922

1 reference

Emerging therapies for hepatitis C virus infection

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

The scientific challenge of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Recent advances in the molecular biology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Candidate targets for hepatitis C virus-specific antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Novel approaches to the treatment of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Hepatitis C virus protease inhibitors: current progress and future challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

1-Aminocyclopropaneboronic acid: synthesis and incorporation into an inhibitor of hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3-4A proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Solid phase synthesis of peptide aldehyde protease inhibitors. Probing the proteolytic sites of hepatitis C virus polyprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Alpha-ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Peptide-based inhibitors of the hepatitis C virus serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Product inhibition of the hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Optimization of the P'-region of peptide inhibitors of hepatitis C virus NS3/4A protease

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Substrate specificity of the hepatitis C virus serine protease NS3.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Aromatic rings act as hydrogen bond acceptors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Amino-aromatic interactions in proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Expression and purification of recombinant full-length NS3 protease-helicase from a new variant of Hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Use of a fluorescence plate reader for measuring kinetic parameters with inner filter effect correction

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

An all atom force field for simulations of proteins and nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Semianalytical treatment of solvation for molecular mechanics and dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

Structure of the hepatitis C virus RNA helicase domain

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900310-3

7 January 2021

10.1016/S0968-0896(02)00310-3

Identifiers

DOI

1 reference

27 June 2017

1 reference